Oral Oresentation 4

3:36 PM - 3:42 PM JST(6:36 AM - 6:42 AM UTC)

[O04-02] Efficacy of mirikizumab in treating East Asian biologic-failed patients with Crohn's disease: a post hoc subanalysis of the global phase 3 VIVID-1 study

*Minhu Chen¹, Baili Chen¹, Yan Chen², Wen Tang³, Zhe Zhang⁴, Bruce Sands⁵, Tae Oh Kim⁶, Wentao Luo⁷, Masaru Tanaka⁸, Frederick Durand⁹, Jiawei Xu⁷, Tadakazu Hisamatsu¹⁰ (1. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2. The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 3. The Second Affiliated Hospital of Soochow University, Suzhou, China, 4. Shengjing Hospital of China Medical University, Shenyang, China, 5. Icahn School of Medicine at Mount Sinai, New York, NY, USA, 6. Inje University Haeundae Paik Hospital, Busan, South Korea, 7. Eli Lilly and Company, Shanghai, China, 8. Eli Lilly Japan K.K., Kobe, Japan, 9. Eli Lilly and Company, Indianapolis, USA, 10. Kyorin University School of Medicine, Tokyo, Japan)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.